Lakefront Biotherapeutics NV current report, Q4 FY2019

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of October 2019. The filing serves to incorporate by reference a press release dated October 28, 2019, regarding a material event. The registrant is a foreign private issuer incorporated in Belgium.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative data table.

Material Changes

The filing references a press release issued on October 28, 2019, as Exhibit 99.1. However, the text of the press release is not included in the provided input, so specific material changes or operational updates cannot be summarized from this document alone.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, or specific risk factors. It notes that the information is incorporated by reference into Registration Statements on Forms F-3 and S-8. Quotes from Piet Wigerinck and Markus Enzelberger are explicitly excluded from the incorporation by reference.

Investor Verification Checklist

  • Verify the actual content of the press release dated October 28, 2019 (Exhibit 99.1), which is referenced but not included in this text.
  • Confirm the correct registrant name is Galapagos NV, as the metadata provided listed Lakefront Biotherapeutics NV.
  • Review the referenced Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.